Insights from 2023 WCLC
WCLC 2023 Insights: "Phase 3 AEGEAN Study - Neoadjuvant Durvalumab + Chemo Followed by Adjuvant Durvalumab in Resectable EGFRm NSCLC"
By
Insights from 2023 WCLC
FEATURING
David Harpole
By
Insights from 2023 WCLC
FEATURING
David Harpole
Login to view comments.
Click here to Login
Videos